Science At BMS

Join us at NPI 2026 for a focused look into schizophrenia. Hara Oyedeji, DNP, will explore the clinical and biological complexity of schizophrenia and its evolving treatment landscape.

Our teams are pursuing investigational therapies across the continuum of care with the hope to slow Alzheimer’s disease progression and help patients and families better manage behavioral symptoms. Learn how we’re making a difference: bit.ly/4sLWDh5 #ADPD2026 #OneBMS

Phase 1 data for our MTA-cooperative PRMT5 inhibitor in patients with pancreatic adenocarcinoma and homozygous MTAP deletion will be presented at the 2026 #ESMOTAT Congress. Find our session on Monday, March 16, at 10am ET/ 4pm CET. bit.ly/4lps2Dz

We’re pioneering multiple strategies for targeted protein degradation to reshape the meaning of “undruggable” and expand possibilities in blood cancers and beyond: bit.ly/3OVEaA3 #MyelomaACTIONMonth #OneBMS

From breaking barriers to driving innovation, women are at the heart of science and discovery. This International Women’s Day, we honor their impact and the future they continue to build. Learn more about our work: bit.ly/40xk7ul #IWD2026 #ScienceFirsthand #OneBMS

HCM affects 1 in 500 people. Up to 80% remain undiagnosed. Two leading cardiologists, an elite NFL athlete and a fierce patient advocate join Dr. Small in exploring a new era of diagnostics and treatment. HCM has entered a new chapter. Have we? Watch now: bit.ly/3MvuzPD

On the International Day of Women and Girls in Science, our scientists discuss how supportive environments and strong mentors can open doors for everyone in STEM. #OneBMS #IDWGS #WomeninScience

Explore the latest data on TRK inhibition for patients with locally advanced or metastatic NTRK-positive solid tumors – the updated results from TRIDENT-1, published in @NatureMedicine. @BenjaminBesseMD, @bensolomon1, @alexdrilon #lungcancer #NTRK #LCSM go.nature.com/4c98jFi

As #ISC26 brings the global stroke community together, we’re focused on the role our collaboration with @JNJInnovMed can play in addressing the unmet needs that remain for people living with the risk of stroke. Learn more: bit.ly/4bs1Uot #OneBMS

CELMoD agents, ligand-directed degraders and degrader antibody conjugates are transforming how targeted protein degradation may improve patient outcomes. See how biology, AI and real-world insights are fostering breakthroughs: bit.ly/4k7rd1t #ScienceFirsthand #OneBMS

The #CARTcelltherapy ecosystem is evolving & we’re advancing with it. Read our latest #DecodedByBMS article to see how we’re expanding innovation & collaborating with industry partners to drive access to this potentially transformative treatment option: bit.ly/498DEGg

Tomorrow at #SABCS25, Dr. @GustavoWerutsky will share the study design of the global phase 2/3 IZABRIGHT-Breast01 trial evaluating an EGFR×HER3 bispecific ADC in TNBC or ER-low/HER2-negative breast cancer. Enrolling now. Join the poster session at 12:30PM CST in the Exhibit Hall

Tomorrow at #SABCS25, Dr. Schmid will share the study design of the global phase 3 ROSETTA Breast-01 trial evaluating a PD-L1 x VEGF-A bispecific antibody plus chemotherapy in PD-L1 negative TNBC. Join the poster session at 12:30pm CST in Exhibit Hall

Tomorrow at #SABCS25, Dr. Schmid will present preliminary data from a global multicohort phase 2 trial of a PD-L1 x VEGF-A bispecific antibody plus chemotherapy for 1L/2L+ locally advanced/metastatic TNBC. Join the poster session at 12:30pm CST in Exhibit Hall

At #ASH25, we are showcasing the future of CAR T cell therapy & steps that make this personalized approach possible for patients. Learn more about the CAR T cell therapy process & how it continues to evolve for people living with certain blood cancers. bit.ly/4iKn2aY

Hear San Diego scientist, Goldie, share her perspective on how we’re shaping the next generation of targeted protein degraders. See how we’re building on our legacy to drug the “undruggable” in blood cancer and beyond: bit.ly/4oBUge5 #ASH25 #ScienceFirsthand #OneBMS

Day 3 of #ASH25 focuses on real-world impact. Explore new data on CD19 #CART therapy in #LBCL with 3 research from @KrishPatelMD, Dr. John Baird and @mshadman. Join the conversation on breaking barriers and expanding CAR-T access for more patients.

We're leveraging 3 modalities of targeted protein degradation–CELMoD agents, ligand-directed degraders & degrader antibody conjugates–to create opportunities for breakthroughs that make a difference for patients. Explore our approach: bit.ly/3MHEwZG #ASH25 #OneBMS

Continue Day 2 at #ASH25 by catching Dr. Manali Kamdar’s (@mana1981) presentation on 4-year long-term follow-up from the TRANSFORM study. Share your patient stories of CD19 #CART cell therapy for r/r #LBCL. bit.ly/44Penyg

Kick off Day 2 of #ASH25 with a CD19 #CART cell therapy presentation in #FL. @drsairahahmed shares long-term 3-year outcomes across patient subgroups–including those with high-risk disease, from the TRANSCEND FL study. bit.ly/4plAAMJ